European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases Evidence‐Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe

Guarino, Alfredo; Ashkenazi, Shai; Gendrel, D.; Vecchio, Andrea Lo; Shamir, Raanan; Szajewska, Hania

doi:10.1097/mpg.0000000000000375

Cited by 687 publications

(804 citation statements)

References 50 publications

Supporting

Mentioning

523

Contrasting

Unclassified

199

Order By: Relevance

“…To give a few examples, effects were documented and supported by meta-analysis in antibiotics-associated diarrhea [118], gastroenteritis [119,120], irritable bowel syndrome (IBS) and gut comfort [121], lactose digestion [122], IBD (UC and pouchitis) [123], Clostridium difficile diarrhea (single RCTs) [124].…”

Section: Probiotics Of First Generationmentioning

confidence: 99%

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

2017

View full text Add to dashboard Cite

Summary From the moment of birth, each human being builds a microbe-host symbiosis which is key for the preservation of its health and well-being. This personal symbiotic coexistence is the result of progressive enrichments in microorganism diversity through external supplies. This diversity is nowadays massively overthrown by drastic changes related to clinical practice in birth management, environmental exposure, nutrition and healthcare behaviors. The last two generations have been the frame of massive modifications in life and food habits, with people being more and more sedentary, overfed and permeated with drugs and pollutants. We are now able to measure the impact of these changes on the gut microbiota diversity. Concomitantly, these modifications of lifestyle were associated with a dramatic increase in incidence of immune-mediated diseases including metabolic, allergic and inflammatory diseases and most likely neurodegenerative and psychiatric disorders. Microbiota is becoming a hot topic in the scientific community and in the mainstream media. The number of scientific publications increased by up to a factor three over the last five years, with gastrointestinal and metabolic diseases being the most productive areas. In the intellectual property landscape, the patent families on microbiota have more than doubled in the meantime. In parallel, funding either from National Institutes (e.g. from NIH which funds research mainly in the field of allergies, infections, cancer and cardiovascular diseases, from the White House which launched the national microbiome initiative) or by pharmaceutical companies follow the same trend, showing a boost and a strong support in the research field on microbiota. All major health players are investing in microbiome research as shown by the number of deals signed and by funding during 2015. The Giens round table addressed how the medicine of tomorrow, considering human beings as a human-microbe symbiotic supraorganism, could leverage microbiome knowledge and tools. The rationale for our working group has been structured around four domains of innovation that could derive from ongoing efforts in deciphering the interactions between human cells and intestinal microbiome as a central component of human health, namely: (1) development of stratification and monitoring tools; (2) identification of new target and drug discovery, as a part of our supra-genome; (4) exploitation of microbiota as a therapeutic target that can be modulated; (4) and finally as a source of live biotherapeutics and adjuvants. These four streams will exemplify how microbiota has changed the way we consider a wide range of chronic and incurable diseases and the consequences of long-lasting dysbiosis. In-depth microbiota analysis is opening one of the broadest fields of investigation for improving human and animal health and will be a source of major therapeutic innovations for tackling today's medical unmet needs. We thus propose a range of recommendations for basic researchers, care givers as well as for hea...

show abstract

Section: Probiotics Of First Generationmentioning

confidence: 99%

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

2017

View full text Add to dashboard Cite

show abstract

“…La diarrea aguda suele durar <7 días y no >14 días y los vómitos de 2 a 3 días. (Diarrea prolongada >7 y <14 días; Diarrea crónica (1,2,3) >14 días).…”

Section: Guía De Manejo De La Gastroenteritis Aguda/enfermedad Diarreunclassified

“…A menudo se asocia a un aumento de la frecuencia, pero esto puede no ser evidente en el momento de la presentación, por lo que un cambio repentino de la consistencia (suelta o acuosa) y/o vómitos, ya pueden hacer sospechar (1,3) un cuadro de gastroenteritis.…”

Section: Guía De Manejo De La Gastroenteritis Aguda/enfermedad Diarreunclassified

“…A medida que la deshidratación progresa, la pérdida de líquidos se puede manifestar por incremento de la sed, irritabilidad, disminución en la turgencia de la piel, ojos hundidos, fontanela deprimida (en el lactante < 1 8 m e s e s ) y a u s e n c i a d e l á g r i m a s . E n l a deshidratación grave, estos signos y síntomas serán más evidentes o se presentarán con choque hipovolémico, alteración del estado de conciencia, disminución del gasto urinario y del flujo sanguíneo, alterando la perfusión periférica, que pueden conducir a la muerte si no se corrigen (1,3,5,6) adecuadamente.…”

Section: Clínicaunclassified

“…Sin embargo no hay un signo clínico único que permita establecer de manera fiable la presencia o la severidad de la deshidratación, y la combinación de (1,3,5) varios hallazgos mejora la capacidad diagnóstica.…”

Section: Clínicaunclassified

See 2 more Smart Citations

Consensus Guideline on Acute Gastroenteritis in the Emergency Department. Emergency Medicine Committee of SLACIP (Latin American Society of Pediatric Intensive Care)

Iramain

Jara

Tovilla

et al. 2017

Pediatr. (Asunción)

View full text Add to dashboard Cite

This document aims to provide an updated guideline for the diagnosis and management of acute gastroenteritis in pediatrics, as this disease is one of the main causes of consultations and hospitalizations. By performing an exhaustive review of the literature to produce a useful tool, this proposal aims to reduce the impact of the disease incidence, morbidity and mortality. The goal of gastroenteritis treatment is to prevent dehydration and electrolyte imbalance that it can produce, with adequate liquids, oral rehydration salts and maintenance of oral feeding. The causes of this disease are mostly viral and the criteria for antibiotic use is controversial. Treatment modalities to reduce the time of illness as well as the frequency of diarrhea are, in many cases, currently under study; therefore, guided, structured and systematized management will ensure the successful treatment of gastroenteritis in most children.

show abstract

Effect of Dilute Apple Juice and Preferred Fluids vs Electrolyte Maintenance Solution on Treatment Failure Among Children With Mild Gastroenteritis

Freedman

Willan

Boutis

et al. 2016

JAMA

View full text Add to dashboard Cite

European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases Evidence‐Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe

Abstract: Acute gastroenteritis is best managed using a few simple, well-defined medical interventions.

Cited by 687 publications

References 50 publications

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect?

Consensus Guideline on Acute Gastroenteritis in the Emergency Department. Emergency Medicine Committee of SLACIP (Latin American Society of Pediatric Intensive Care)

Effect of Dilute Apple Juice and Preferred Fluids vs Electrolyte Maintenance Solution on Treatment Failure Among Children With Mild Gastroenteritis

Contact Info

Product

Resources

About